The DOI matches its Crossref record; 14 of the 14 references it cites were found in a registry or an index.
Five-Year Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma
Open accessAbstract
BACKGROUNDNivolumab plus ipilimumab or nivolumab alone resulted in longer progression-free and overall survival than ipilimumab alone in a trial involving patients with advanced melanoma.We now report 5-year outcomes in the trial. METHODSWe randomly assigned patients with previously untreated advanced melanoma to receive one of the following regimens: nivolumab (at a dose of 1 mg per kilogram of body weight) plus ipilimumab (3 mg per kilogram) every 3 weeks for four doses, followed by nivolumab (3 mg per kilogram every 2 weeks); nivolumab (3 mg per kilogram every 2 weeks) plus ipilimumab-matched placebo; or ipilimumab (3 mg per kilogram every 3 weeks for four doses) plus nivolumab-matched placebo.The two primary end points were progression-free survival and overall survival in the nivolumab-plus-ipilimumab group and in the nivolumab group, as compared with the ipilimumab group. RESULTSAt a minimum follow-up of 60 months, the median overall survival was more than 60.0 months (median not reached) in the nivolumab-plus-ipilimumab group and 36.9 months in the nivolumab group, as compared with 19.9 months in the ipilimumab group (hazard ratio for death with nivolumab plus ipilimumab vs. ipilimumab, 0.52; hazard ratio for death with nivolumab vs. ipilimumab, 0.63).Overall survival at 5 years was 52% in the nivolumab-plus-ipilimumab group and 44% in the nivolumab group, as compared with 26% in the ipilimumab group.No sustained deterioration of health-related quality of life was observed during or after treatment with nivolumab plus ipilimumab or with nivolumab alone.No new late toxic effects were noted. CONCLUSIONSAmong patients with advanced melanoma, sustained long-term overall survival at 5 years was observed in a greater percentage of patients who received nivolumab plus ipilimumab or nivolumab alone than in those who received ipilimumab alone, with no apparent loss of quality of life in the patients who received regimens containing nivolumab.(Funded by Bristol-Myers Squibb and others; CheckMate 067 ClinicalTrials.govnumber, NCT01844505.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“In many cancers, nivolumab in combination with ipilimumab improves response rates compared to either agent alone, but the combination has not been evaluated in childhood cancer.”
From A Phase I/II Trial of Nivolumab plus Ipilimumab in Children and Young Adults with Relapsed/Refractory Solid Tumors: A Children's Oncology Group Study ADVL1412 (2022) · cites this paper as [12]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Nivolumab, a PD-1 inhibitor, in combination with ipilimumab, a CTLA-4 inhibitor, has shown favourable efficacy outcomes and manageable safety profiles across multiple tumour types.”
From Nivolumab plus ipilimumab versus lenvatinib or sorafenib as first-line treatment for unresectable hepatocellular carcinoma (CheckMate 9DW): an open-label, randomised, phase 3 trial (2025) · cites this paper as [12]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“While immune checkpoint inhibitors (ICIs) have greatly enhanced clinical outcomes across multiple cancer types,1, 2, 3”
From irAE-GPT: leveraging large language models to identify immune-related adverse events in electronic health records and clinical trial datasets (2026) · cites this paper as [3]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“In unresectable or metastatic melanoma, overall survival at 5 years is 52% following nivolumab plus ipilimumab compared to 44% for nivolumab alone and 26% for ipilimumab alone12,13.”
The check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“Evidence for benefit of nivolumab plus ipilimumab compared to single agent ICI has also been demonstrated in patients with advanced renal cell cancer, microsatellite high/deficient mismatch repair (MSI-hi/dMMR) metastatic colorectal cancer12,14,15, hepatocellular carcinoma16, and non-small cell, EGFR/ALK wild type lung cancer17–19.”
From A Phase I/II Trial of Nivolumab plus Ipilimumab in Children and Young Adults with Relapsed/Refractory Solid Tumors: A Children's Oncology Group Study ADVL1412 (2022) · cites this paper as [12]
Experimental — accuracy not yet measured
In the citing paper
“Melanomas and urothelial carcinomas that are intrinsically resistant to anti-PD-1/PD-L1 therapy show elevated TGF-β signaling, particularly in the stromal compartment of immune excluded tumors21,77,228,361.”
From TGFβ biology in cancer progression and immunotherapy (2021) · cites this paper as [361]
In the citing paper
“Multiple clinical trials with combined blockade of CTLA4 and PD-1/PD-L1 demonstrated higher response rates than either monotherapy, in different cancer types including melanoma ( 54, 55 ), hepatocellular carcinoma ( 56 ), renal cell carcinoma (RCC; refs.57, 58 ), NSCLC ( 59 ), malignant pleural mesothelioma ( 60 ), and colorectal cancer (MSI-H/dMMR; ref. 61 ).”
From The Next Decade of Immune Checkpoint Therapy (2021) · cites this paper as [55]
In the citing paper
“Long-term follow-up has demonstrated durable survival benefi t for a subset of patients with melanoma and RCC, and combination therapy with ICT is under active investigation for a number of tumor types ( 55,58 ).”
From The Next Decade of Immune Checkpoint Therapy (2021) · cites this paper as [55]
In the citing paper
“Anti-PD-1/PD-L1 agents pared with chemotherapy have also improved response rates and survival in many diseases including lung cancer, triple negative breast cancer, head and neck squamous cell carcinoma, and others.12–14”
From Endocrine toxicities of immune checkpoint inhibitors (2021) · cites this paper as [13]
In the citing paper
“The results of CheckMate-069, CheckMate-067, and CheckMate-142 showed that ipilimumab plus nivolumab significantly improved the outcomes of patients, relative to ipilimumab or nivolumab monotherapies [132–134].”
From Combination strategies with PD-1/PD-L1 blockade: current advances and future directions (2022) · cites this paper as [133]
In the citing paper
“Until now, the FDA has approved the ipilimumab plus nivolumab for melanoma, RCC, MSI-H/dMMR colorectal cancer, HCC, PD-L1 positive NSCLC, and malignant pleural mesothelioma (Table 5) [132–138].”
From Combination strategies with PD-1/PD-L1 blockade: current advances and future directions (2022) · cites this paper as [133]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma
Larkin, J., Chiarion-Sileni, V., Gonzalez, R., Grob, J. J., Cowey, C. L., Lao, C. D., Schadendorf, D., Dummer, R., Smylie, M., Rutkowski, P., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1504030 · Cited by 8,157
Self-citationOverall Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma
Wolchok, J. D., Chiarion-Sileni, V., Gonzalez, R., Rutkowski, P., Grob, J.-J., Cowey, C. L., Lao, C. D., Wagstaff, J., Schadendorf, D., Ferrucci, P. F., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1709684 · Cited by 5,357
Self-citation(1997) · doi:10.1097/00005650-199711000-00002 · Cited by 4,544
Hodi, F. S., Chiarion-Sileni, V., Gonzalez, R., Grob, J.-J., Rutkowski, P., Cowey, C. L., Lao, C. D., Schadendorf, D., Wagstaff, J., Dummer, R., et al. (2018) · The Lancet Oncology · doi:10.1016/s1470-2045(18)30700-9 · Cited by 1,399
Five-year outcomes with dabrafenib plus trametinib in metastatic melanoma
Robert, C., Grob, J. J., Stroyakovskiy, D., Karaszewska, B., Hauschild, A., Levchenko, E., Chiarion Sileni, V., Schachter, J., Garbe, C., Bondarenko, I., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1904059 · Cited by 1,389
Self-citationCombined Nivolumab and Ipilimumab in Melanoma Metastatic to the Brain
Tawbi, H. A., Forsyth, P. A., Algazi, A. P., Hamid, O., Hodi, F. S., Moschos, S. J., Khushalani, N. I., Lewis, K. D., Lao, C. D., Postow, M. A., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1805453 · Cited by 1,336
Self-citationLong, G. V., Atkinson, V. G., Lo, S., Sandhu, S. K., Guminski, A. D., Brown, M. P., Wilmott, J. S., Edwards, J. J., Gonzalez, M., Scolyer, R. A., et al. (2018) · The Lancet Oncology · doi:10.1016/s1470-2045(18)30139-6 · Cited by 1,001
Self-citationEstimation of minimally important differences in EQ-5D utility and VAS scores in cancer
Pickard, A. S., Neary, M. P., & Cella, D. F. (2007) · Health and Quality of Life Outcomes · doi:10.1186/1477-7525-5-70 · Cited by 932
Lebbé, C., Meyer, N., Mortier, L., Marquez-Rodas, I., Robert, C., Rutkowski, P., Menzies, A. M., Eigentler, T., Ascierto, P. A., Smylie, M., et al. (2019) · Journal of Clinical Oncology · doi:10.1200/jco.18.01998 · Cited by 408
Self-citationKhair, D. O., Bax, H. J., Mele, S., Crescioli, S., Pellizzari, G., Khiabany, A., Nakamura, M., Harris, R. J. C., French, E., Hoffmann, R. M., et al. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2019.00453 · Cited by 252
Flagged first, then by citations
Cited by
Sorted by citations
Items 601–700 of 1,003
Robert, C., Gastman, B., Gogas, H. J., Rutkowski, P., Long, G. V., Chaney, M. F., Joshi, H., Lin, Y., SNYDER, W. J., & Chesney, J. A. (2024) · European Journal of Cancer · doi:10.1016/j.ejca.2024.114120 · Cited by 46
Self-citationReschke, R., Enk, A. H., & Hassel, J. C. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25126532 · Cited by 51
“For patients with advanced melanoma treated with a combination of anti-PD-1 and anti-CTLA-4 monoclonal antibodies (mAb), the five-year survival rate now exceeds 50% [1].”
BackgroundLong, G. V., Carlino, M. S., Au‐Yeung, G., Spillane, A. J., Shannon, K. F., Gyorki, D. E., Hsiao, E., Kapoor, R., Thompson, J., Batula, I., et al. (2024) · Nature Medicine · doi:10.1038/s41591-024-03077-5 · Cited by 48
“BRAF and mitogen-activated protein kinase kinase (MEK)-targeted therapies and immune checkpoint inhibitor (ICI) immunotherapy have led to remarkable improvements in response and survival outcomes in the advanced (unresectable stage III or IV melanoma) setting 4,5 .”
Self-citationZhang, J., Peng, Q., Fan, J., Liu, F., Chen, H., Bi, X., Yuan, S., Jiang, W., Pan, T. S., Li, K., et al. (2024) · Journal of Translational Medicine · doi:10.1186/s12967-024-06018-5 · Cited by 49
Zhou, X., Liu, Y., Hu, M., Wang, M., Liu, X., & Huang, L. (2021) · Science Advances · doi:10.1126/sciadv.abb6596 · Cited by 43
Ellingsen, E. B., Mangsbo, S. M., Hovig, E. J., & Gaudernack, G. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.682492 · Cited by 46
Hamada, K., Yoshimura, K., Hirasawa, Y., Hosonuma, M., Murayama, M., Narikawa, Y., Ariizumi, H., Ohkuma, R., Shida, M., Kubota, Y., et al. (2021) · Anticancer Research · doi:10.21873/anticanres.15312 · Cited by 46
Fattore, L., Cafaro, G., Martile, M. D., Campani, V., Sacconi, A., Liguoro, D., Marra, E., Bruschini, S., Stoppoloni, D., Cirombella, R., et al. (2022) · Oncogene · doi:10.1038/s41388-022-02547-9 · Cited by 47
“In this context, in stage IV melanoma, five year overall survival rates obtained with the combination of dabrafenib plus tramentinib [2] or ipilimumab plus nivolumab [42] are currently up to 34 and 52%, respectively.”
BackgroundSelf-citationVoronova, V., Vislobokova, A., Mutig, K., Samsonov, M., Peskov, K. V., Sekacheva, M. I., Materenchuk, M. Y., Bunyatyan, N. D., & Lebedeva, S. A. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.1035884 · Cited by 47
Kasago, I. S., Chatila, W. K., Lezcano, C. M., Febres‐Aldana, C. A., Schultz, N. D., Vanderbilt, C., Doğan, S., Bartlett, E. K., D’Angelo, S. P., Tap, W. D., et al. (2023) · Modern Pathology · doi:10.1016/j.modpat.2023.100165 · Cited by 44
Lymph nodes: at the intersection of cancer treatment and progression
Reticker-Flynn, N. E., & Engleman, E. G. (2023) · Trends in Cell Biology · doi:10.1016/j.tcb.2023.04.001 · Cited by 45
New Approaches to Targeted Therapy in Melanoma
Fernandez, M. F., Choi, J. S., & Sosman, J. A. (2023) · Cancers · doi:10.3390/cancers15123224 · Cited by 46
“Despite the unprecedented success of immune checkpoint inhibitors (ICIs), the majority of patients will eventually experie ce disease progression due to primary refractory disease or acquired resistance [4].”
BackgroundHuang, W., Kim, B. S., Zhang, Y., Lin, L., Chai, G., & Zhao, Z. (2024) · Environmental Toxicology · doi:10.1002/tox.24247 · Cited by 44
Zhou, Y., Zhang, Y., Guo, G., Cai, X., Yu, H., Cai, Y., Zhang, B., Hong, S., & Zhang, L. (2020) · Clinical and Translational Medicine · doi:10.1002/ctm2.14 · Cited by 43
Checkpoint Inhibitor Pneumonitis: Mechanisms, Characteristics, Management Strategies, and Beyond
Reuss, J. E., Suresh, K. S., & Naidoo, J. (2020) · Current Oncology Reports · doi:10.1007/s11912-020-00920-z · Cited by 44
Systemic Therapy of Extensive Stage Small Cell Lung Cancer in the Era of Immunotherapy
Ragavan, M. V., & Das, M. S. (2020) · Current Treatment Options in Oncology · doi:10.1007/s11864-020-00762-8 · Cited by 44
Is the Neutrophil-to-Lymphocyte Ratio a Useful Prognostic Indicator in Melanoma Patients?
Cohen, J. T., Miner, T. J., & Vezeridis, M. P. (2020) · Melanoma Management · doi:10.2217/mmt-2020-0006 · Cited by 46
Association between tumor mutation burden and immune infiltration in ovarian cancer
Fan, S., Gao, X., Qin, Q., Li, H., Yuan, Z., & Zhao, S. (2020) · International Immunopharmacology · doi:10.1016/j.intimp.2020.107126 · Cited by 46
Novel adjuvant options for cutaneous melanoma
Dimitriou, F., Long, G. V., & Menzies, A. M. (2021) · Annals of Oncology · doi:10.1016/j.annonc.2021.03.198 · Cited by 44
Self-citationKlein, O., Senko, C., Carlino, M. S., Markman, B., Jackett, L. A., Gao, B., Lum, C., Kee, D., Behren, A., Palmer, J., et al. (2021) · OncoImmunology · doi:10.1080/2162402x.2021.1908771 · Cited by 46
Self-citationMolecular Mechanisms of Resistance to Immune Checkpoint Inhibitors in Melanoma Treatment: An Update
Vukadin, S., Khaznadar, F., Kizivat, T., Včev, A., & Smolić, M. (2021) · Biomedicines · doi:10.3390/biomedicines9070835 · Cited by 47
Unravelling Checkpoint Inhibitor Associated Autoimmune Diabetes: From Bench to Bedside
Wu, L., Tsang, V., Sasson, S. C., Menzies, A. M., Carlino, M. S., Brown, D. A., Clifton-Bligh, R. J., & Gunton, J. E. (2021) · Frontiers in Endocrinology · doi:10.3389/fendo.2021.764138 · Cited by 46
“A 1 year overall survival of 25-35% with previous standard of care chemotherapy (8), increased to 73% with use of combination ICI therapies nivolumab (anti-PD1) and ipilimumab (anti-CTLA4) (9).”
BackgroundSelf-citationMoreau-Bachelard, C., Coquan, E., du Rusquec, P., Paolettí, X., & Tourneau, C. L. (2021) · EClinicalMedicine · doi:10.1016/j.eclinm.2021.101130 · Cited by 43
Role of extracellular matrix architecture and signaling in melanoma therapeutic resistance
Popovic, A., & Tartare‐Deckert, S. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.924553 · Cited by 46
“Notably, the landscape of advanced melanoma treatment has changed drastically in the last decade, following the FDA-approval of immune checkpoint/blockade inhibitors and targeted therapies (4, 29).”
BackgroundRadiopharmaceuticals heat anti-tumor immunity
Sun, Q., Li, J., Ding, Z., & Liu, Z. (2023) · Theranostics · doi:10.7150/thno.79806 · Cited by 43
“Since PD-1/PD-L1 and CTLA-4 possessed different mechanisms of action, the combination therapy using these two inhibitors has also been studied and applied [117, 118].”
T cell-based cancer immunotherapy: opportunities and challenges
Ma, K., Xu, Y., Cheng, H., Tang, K., Ma, J., & Huang, B. (2025) · 中国科学通报：英文版 · doi:10.1016/j.scib.2025.03.054 · Cited by 47
Mixed Response to Immunotherapy in Patients with Metastatic Melanoma
Rauwerdink, D. J. W., Molina, G., Frederick, D. T., Sharova, T., van der Hage, J. A., Cohen, S., & Boland, G. M. (2020) · Annals of Surgical Oncology · doi:10.1245/s10434-020-08657-6 · Cited by 43
Research progress of PD-1/PD-L1 immunotherapy in gastrointestinal tumors
Sun, J., Zheng, Y., Mamun, M., Li, X., Chen, X., & Gao, Y. (2020) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2020.110504 · Cited by 44
Future of immune checkpoint inhibitors: focus on tumor immune microenvironment
Jia, Y., Liu, L., & Shan, B. (2020) · Annals of Translational Medicine · doi:10.21037/atm-20-3735 · Cited by 43
Hu, H., She, L., Liao, M., Shi, Y., Yao, L., Ding, D., Zhu, Y., Zeng, S., Carbone, D. P., & Huang, J. (2020) · Frontiers in Oncology · doi:10.3389/fonc.2020.01649 · Cited by 43
Lynch, F., Katona, L., Jefford, M., Smith, A. B., Shaw, J., Dhillon, H. M., Ellen, S., Phipps‐Nelson, J., Lai-Kwon, J. E., Milne, D., et al. (2020) · Journal of Clinical Medicine · doi:10.3390/jcm9092969 · Cited by 43
Ziogas, D. C., Gkoufa, A., Cholongitas, Ε., Diamantopoulos, P. T., Anastasopoulou, A. N., Ascierto, P. A., & Gogas, H. J. (2020) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2020-001322 · Cited by 43
Self-citationTumor MHC Expression Guides First-Line Immunotherapy Selection in Melanoma
Shklovskaya, E., Lee, J., Lim, S. Y., Stewart, A., Pedersen, B., Ferguson, P. M., Saw, R. P. M., Thompson, J. F., Shivalingam, B., Carlino, M. S., et al. (2020) · Cancers · doi:10.3390/cancers12113374 · Cited by 43
Self-citationKlein, S., Mauch, C., Brinker, K., Noh, K., Knez, S., Büttner, R., Quaas, A., & Helbig, D. (2021) · Scientific Reports · doi:10.1038/s41598-021-81330-4 · Cited by 43
Umeda, Y., Yoshikawa, S., Kiniwa, Y., Maekawa, T., Yamasaki, O., Isei, T., Matsushita, S., Nomura, M., Nakai, Y., Fukushima, S., et al. (2021) · European Journal of Cancer · doi:10.1016/j.ejca.2021.08.034 · Cited by 43
Friedman, C. F., Spencer, C. N., Cabanski, C. R., Panageas, K. S., Wells, D. K., Ribas, A., Tawbi, H. A., Tsai, K. K., Postow, M. A., Shoushtari, A. N., et al. (2022) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2021-003853 · Cited by 47
Self-citationPredicting cancer immunotherapy response from gut microbiomes using machine learning models
Liang, H., Jo, J., Zhang, Z., MacGibeny, M. A., Han, J., Proctor, D. M., Taylor, M. E., Che, Y., Juneau, P. L., Apolo, A. B., et al. (2022) · Oncotarget · doi:10.18632/oncotarget.28252 · Cited by 42
“Although immunotherapy can significantly improve treatment outcomes amongst different cancer types as compared to other treatment modalities [4], approximately half of patients do not respond to immunotherapy [3, 5, 6].”
BackgroundMolecular imaging to support cancer immunotherapy
van de Donk, P. P., Oosting, S. F., Knapen, D. G., van der Wekken, A. J., Brouwers, A. H., Hooge, M. N. L., de Groot, D. J., & de Vries, E. G. E. (2022) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2022-004949 · Cited by 43
Targeting DNA Damage Response and Immune Checkpoint for Anticancer Therapy
Huang, J.-L., Chang, Y.-T., Hong, Z.-Y., & Lin, C.-S. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23063238 · Cited by 42
“For metastatic melanoma as an example, patient’s long-term survival rate can be extended from 5% to 50% with anti-PD-1 plus anti-CTLA-4 combination therapy [92].”
BackgroundErmer, T., Canavan, M., Maduka, R. C., Li, A. X., Salazar, M. C., Kaminski, M. F., Pichert, M. D., Zhan, P. L., Mase, V. J., Kluger, H. M., et al. (2022) · JAMA Network Open · doi:10.1001/jamanetworkopen.2022.19535 · Cited by 42
Peng, K., Zhang, Y., Liu, D.-Y., & Chen, J. (2023) · Cancer Cell International · doi:10.1186/s12935-023-02862-5 · Cited by 42
“Antibodies targeting the immune checkpoints, such as cytotoxic T-lymphocyte–associated antigen 4 (anti-CTLA-4) and programmed cell death protein-1 (anti-PD-1), some patients have achieved long-term benefits [5].”
BackgroundActivity and Safety of First-Line Treatments for Advanced Melanoma: A Network Meta-Analysis
Boutros, A., Tanda, E. T., Croce, E., Catalano, F., Ceppi, M., Bruzzone, M., Cecchi, F., Arecco, L., Fraguglia, M., Pronzato, P., et al. (2022) · European Journal of Cancer · doi:10.1016/j.ejca.2023.04.010 · Cited by 50
Lorentzen, C. L., Kjeldsen, J. W., Ehrnrooth, E., Andersen, M. H., & Svane, I. M. (2023) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2023-006755 · Cited by 42
Moehler, M. H., Xiao, H., Blum, S. I., Elimova, E. C., Cella, D. F., Shitara, K., Ajani, J. A., Janjigian, Y. Y., Marcelo Garrido, S., Shen, L., et al. (2023) · Journal of Clinical Oncology · doi:10.1200/jco.23.00170 · Cited by 42
T cell exhaustion in human cancers
Kang, K., Lin, X., Chen, P., Liu, H., Liu, F., Xiong, W., Li, G., Yi, M., Li, X., Wang, H., et al. (2024) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2024.189162 · Cited by 49
Yin, X., Song, X., Deng, W., BLAKE, N. W., Luo, X., & Meng, J. (2024) · Frontiers in Oncology · doi:10.3389/fonc.2024.1483454 · Cited by 44
Burgers, F. H., van der Mijn, J. C., Seijkens, T. T. P., Jedema, I., Bex, A., & Haanen, J. B. A. G. (2025) · Nature Reviews Nephrology · doi:10.1038/s41581-025-00983-w · Cited by 49
“By contrast, long-term clinical benefits of ICI treatment have been observed in people with advanced melanoma, with up to 25% of patients achieving a complete response 18–20 .”
Self-citationSchummer, P., Schilling, B., & Gesierich, A. (2020) · American Journal of Clinical Dermatology · doi:10.1007/s40257-020-00509-z · Cited by 44
Balancing Cancer Immunotherapy Efficacy and Toxicity
Johnson, D. B., Jakubovic, B. D., Sibaud, V., & Sise, M. E. (2020) · The Journal of Allergy and Clinical Immunology In Practice · doi:10.1016/j.jaip.2020.06.028 · Cited by 46
Neoadjuvant immunotherapy for melanoma
Lee, A. Y., & Brady, M. S. (2020) · Journal of Surgical Oncology · doi:10.1002/jso.26229 · Cited by 43
Wu, C., Yang, C., Peng, M., Huang, P., Chang, C., Yeh, K., Chen, C., Wang, C., Hsu, C., Chen, I., et al. (2020) · BMC Cancer · doi:10.1186/s12885-020-07508-7 · Cited by 42
Nahar, K. J., Rawson, R. V., Ahmed, T., Tattersall, S., Sandanayake, N. S., Kiely, C. J., Lo, S., Carlino, M. S., Palendira, U., Scolyer, R. A., et al. (2020) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2020-001488 · Cited by 43
Self-citationLi, M., Zhao, J., Yang, R., Cai, R., Liu, X., Xie, J., Shu, B., & Qi, S. (2022) · Cancer Science · doi:10.1111/cas.15303 · Cited by 42
Melanoma in pregnancy: Diagnosis and management in early-stage and advanced disease
Carter, T. J., George, C., Harwood, C. A., & Nathan, P. (2022) · European Journal of Cancer · doi:10.1016/j.ejca.2022.02.016 · Cited by 44
“From current data, survival/relapse rates appear to plateau 3 e 4 years following treatment initiation in stage IV/III patients [112,113].”
BackgroundCoukos, A., Vionnet, J., Obéid, M., Bouchaab, H., Peters, S., Latifyan, S., Wicky, A. M., Michielin, O. A., Chtioui, H., Moradpour, D., et al. (2022) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2022-005635 · Cited by 43
Marsavela, G., McEvoy, A. C., Pereira, M. R., Reid, A. L., Al‐Ogaili, Z., Warburton, L., Khattak, M. A., Abed, A., Meniawy, T. M., Millward, M., et al. (2021) · British Journal of Cancer · doi:10.1038/s41416-021-01507-6 · Cited by 42
The Evolving Landscape of Fecal Microbial Transplantation
Shao, T., Hsu, R., Hacein-Bey, C., Zhang, W., Gao, L., Kurth, M. J., Zhao, H., Shuai, Z., & Leung, P. S. C. (2023) · Clinical Reviews in Allergy & Immunology · doi:10.1007/s12016-023-08958-0 · Cited by 43
Nanodrug removes physical barrier to promote T-cell infiltration for enhanced cancer immunotherapy
Xiao, Z., Tan, Y., Cai, Y., Huang, J., Wang, X., Li, B., Lin, L., Wang, Y., Shuai, X., & Zhu, K. (2023) · Journal of Controlled Release · doi:10.1016/j.jconrel.2023.02.029 · Cited by 42
Mechanisms and research advances in mRNA antibody drug-mediated passive immunotherapy
Zhao, Y., Gan, L., Ke, D., Chen, Q., & Fu, Y. (2023) · Journal of Translational Medicine · doi:10.1186/s12967-023-04553-1 · Cited by 45
“For example, the marketed drug Opdualag (Nivolumab + Relatlimab) is combined with two immune checkpoint inhibitors, PD-1 and LAG-3, in order to obtain better anti-tumor effects [147].”
BackgroundUveal melanoma immunogenomics predict immunotherapy resistance and susceptibility
Leonard‐Murali, S., Bhaskarla, C., Yadav, G. S., Maurya, S. K., Galiveti, C. R., Tobin, J. A., Kann, R. J., Ashwat, E., Murphy, P. S., Chakka, A. B., et al. (2024) · Nature Communications · doi:10.1038/s41467-024-46906-4 · Cited by 45
Advances and clinical applications of immune checkpoint inhibitors in hematological malignancies
Sun, W., Hu, S., & Wang, X. (2024) · 癌症：英文版 · doi:10.1002/cac2.12587 · Cited by 42
“In 2014, the first PD-1 targeting agent, pembrolizumab, was approved by U.S. Food and Drug Administration (FDA) for melanoma treatment [6, 7].”
BackgroundTriantafyllou, E., Gudd, C. L. C., & Possamai, L. A. (2024) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/s41575-024-01019-7 · Cited by 49
“Combination therapies, including ipilimumab plus nivolumab and durvalumab plus tremelimumab, have demonstrated higher response rates and better clinical outcomes than monotherapies in certain tumour types 36–38 .”
Nivolumab plus relatlimab in advanced melanoma: RELATIVITY-047 4-year update
Lipson, E. J., Hodi, F. S., Tawbi, H. A.-H., Schadendorf, D., Ascierto, P. A., Matamala, L., Gutiérrez, E. C., Rutkowski, P. L., Gogas, H. J., Lao, C., et al. (2025) · European Journal of Cancer · doi:10.1016/j.ejca.2025.115547 · Cited by 44
Self-citationAamdal, E., Inderberg, E. M., Ellingsen, E. B., Rasch, W., Brunsvig, P. F., Aamdal, S., Heintz, K., Vodák, D., Nakken, S., Hovig, E. J., et al. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.663865 · Cited by 41
Long, G. V., Robert, C., Butler, M. O., Couture, F., Carlino, M. S., O'Day, S. J., Atkinson, V. G., Cebon, J. S., Brown, M. P., Dalle, S., et al. (2021) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-21-0793 · Cited by 41
Self-citationNRF2 and Key Transcriptional Targets in Melanoma Redox Manipulation
Carpenter, E. L., Becker, A. L., & Indra, A. K. (2022) · Cancers · doi:10.3390/cancers14061531 · Cited by 42
“who received nivolumab (anti-PD-1) plus ipilimumab (anti-CTLA-4) compared to ipilimumab alone [32,33].”
BackgroundLatest Advances in the Use of Therapeutic Focused Ultrasound in the Treatment of Pancreatic Cancer
Mouratidis, P., & ter Haar, G. (2022) · Cancers · doi:10.3390/cancers14030638 · Cited by 40
In Vivo Syngeneic Tumor Models with Acquired Resistance to Anti–PD-1/PD-L1 Therapies
Denis, M., Grasselly, C., Choffour, P., Wierinckx, A., Mathé, D., Chettab, K., Tourette, A., Talhi, N., Bourguignon, A., Birzele, F., et al. (2022) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-21-0802 · Cited by 46
Roles and therapeutic implications of m6A modification in cancer immunotherapy
Pan, J., Huang, T., Deng, Z., & Zou, C. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1132601 · Cited by 39
“Nivolumab plus ipilimumab has demonstrated durable overall survival benefit in melanoma (49), renal cell carcinoma (50), and NSCLC (51).”
BackgroundGNAQ and GNA 11 mutant nonuveal melanoma: a subtype distinct from both cutaneous and uveal melanoma
Livingstone, E., Zaremba, A., Horn, S., Ugurel, S., Casalini, B., Schlaak, M. S., Hassel, J. C., Herbst, R. A., Utikal, J. S., Weide, B., et al. (2020) · British Journal of Dermatology · doi:10.1111/bjd.18947 · Cited by 42
Self-citationOptimal treatment strategy for metastatic melanoma patients harboring BRAF-V600 mutations
Giunta, E. F., Falco, V. D., Napolitano, S., Argenziano, G., Brancaccio, G., Moscarella, E., Ciardiello, D., Ciardiello, F., & Troiani, T. (2020) · Therapeutic Advances in Medical Oncology · doi:10.1177/1758835920925219 · Cited by 40
Anti-PD-1 and Anti-PD-L1 Monoclonal Antibodies in People Living with HIV and Cancer
Lurain, K. A., Ramaswami, R., Yarchoan, R., & Uldrick, T. S. (2020) · Current HIV/AIDS Reports · doi:10.1007/s11904-020-00525-y · Cited by 42
Relecom, A., Merhi, M., Inchakalody, V. P., Shahab Uddin, M. S., Rinchai, D., Bedognetti, D., & Dermime, S. (2021) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-021-01872-3 · Cited by 41
Bispecific Antibodies to PD-1 and CTLA4: Doubling Down on T Cells to Decouple Efficacy from Toxicity
Burton, E. M., & Tawbi, H. A. (2021) · Cancer Discovery · doi:10.1158/2159-8290.cd-21-0257 · Cited by 40
The Abscopal Effect in the Era of Checkpoint Inhibitors
Kodet, O., Němejcová, K., Strnadová, K., Havlínová, A., Dundr, P., Krajsová, I., Štork, J., Smetana, K., & Lacina, L. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22137204 · Cited by 42
Farlow, J. L., Brenner, J. C., Lei, Y. L., & Chinn, S. B. (2021) · Oral Oncology · doi:10.1016/j.oraloncology.2021.105420 · Cited by 41
Aiming at a Tailored Cure for ERBB2 -Positive Metastatic Breast Cancer
Tarantino, P., Curigliano, G., Parsons, H. A., Lin, N., Krop, I. E., Mittendorf, E. A., Waks, A. G., Winer, E. P., & Tolaney, S. M. (2022) · JAMA Oncology · doi:10.1001/jamaoncol.2021.6597 · Cited by 41
PD-1 blockade and CDK4/6 inhibition augment nonoverlapping features of T cell activation in cancer
Ali, L. R., Garrido-Castro, A. C., Lenehan, P. J., Böllenrücher, N., Stump, C. T., Dougan, M. L., Goel, S., Shapiro, G. I., Tolaney, S. M., & Dougan, S. K. (2023) · The Journal of Experimental Medicine · doi:10.1084/jem.20220729 · Cited by 40
Tran, T. T. T., Caulfield, J. I., Zhang, L., Schoenfeld, D. A., Djureinovic, D., Chiang, V., Oria, V. O., Weiss, S. A., Olino, K. L., Jilaveanu, L. B., et al. (2023) · JCI Insight · doi:10.1172/jci.insight.157347 · Cited by 41
Sharma, S., Kumar, C., Kushwaha, H., Sahil, Jha, S. K., Chawla, S., Sharma, A., Midha, T., & Huddar, V. G. (2025) · Ayush journal of integrative oncology. · doi:10.4103/ajio.ajio_3_25 · Cited by 39
Human Plasmacytoid Dendritic Cells and Cutaneous Melanoma
Monti, M., Consoli, F., Vescovi, R., Bugatti, M., & Vermi, W. (2020) · Cells · doi:10.3390/cells9020417 · Cited by 41
Bleicher, J. M., Swords, D. S., Mali, M. E., McGuire, L., Pahlkotter, M. K., Asare, E. A., Bowles, T. L., & Hyngstrom, J. R. (2020) · Journal of Surgical Oncology · doi:10.1002/jso.26214 · Cited by 39
Tateo, V., Manuzzi, L., Giglio, A. D., Parisi, C., Lamberti, G., Campana, D., & Pantaleo, M. A. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21239056 · Cited by 41
Minimal Residual Disease, Metastasis and Immunity
Badia-Ramentol, J., Linares, J., Gómez‐Llonín, A., & Calon, A. (2021) · Biomolecules · doi:10.3390/biom11020130 · Cited by 39
Biewenga, M., van der Kooij, M. K., Wouters, M. W. J. M., Aarts, M. J. B., van den Berkmortel, F. W. P. J., de Groot, J. W. B., Boers‐Sonderen, M. J., Hospers, G. A. P., Piersma, D., van Rijn, R. S., et al. (2021) · Hepatology International · doi:10.1007/s12072-021-10151-4 · Cited by 40
Self-citationYan, C. W., Saleh, N., Yang, J., Nebhan, C. A., Vilgelm, A. E., Reddy, E. P., Roland, J. T., Johnson, D. B., Chen, S., Shattuck-Brandt, R. L., et al. (2021) · Molecular Cancer · doi:10.1186/s12943-021-01366-y · Cited by 39
Li, Y., Meng, Y., Sun, H., Ye, L., Zeng, F., Chen, X., & Deng, G. (2021) · Journal of Immunotherapy · doi:10.1097/cji.0000000000000392 · Cited by 39
Sun, S. H., Benner, B. N., Savardekar, H., Lapurga, G., Good, L., Abood, D., Nagle, E., Duggan, M. C., Stiff, A. R., DiVincenzo, M. J., et al. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.740890 · Cited by 36
“However, a significant number of patients (24%) still did not respond (27).”
BackgroundPokorny, R., McPherson, J. P., Haaland, B. A., Grossmann, K. F., Luckett, C., Voorhies, B. N., Sageser, D. S., Wallentine, J., Tolman, Z., Hu‐Lieskovan, S., et al. (2021) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2020-001781 · Cited by 39
Fertility preservation and management of pregnancy in melanoma patients requiring systemic therapy
Hassel, J. C., Livingstone, E., Allam, J., Behre, H. M., Bojunga, J., Klein, H. H., Landsberg, J., Nawroth, F., Schüring, A. N., Susok, L., et al. (2021) · ESMO Open · doi:10.1016/j.esmoop.2021.100248 · Cited by 40
Zubiri, L., Molina, G. E., Mooradian, M. J., Cohen, J. V., Durbin, S., Petrillo, L. A., Boland, G. M., Juric, D., Dougan, M. L., Thomas, M. F., et al. (2021) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2021-002886 · Cited by 38
The gut microbiome and melanoma: A review
Makaranka, S., Scutt, F., Frixou, M., Wensley, K. E., Sharma, R., & Greenhowe, J. (2022) · Experimental Dermatology · doi:10.1111/exd.14639 · Cited by 39
Chen, B., Chen, Y., Dragomir, M. P., Chi, D., Chen, W., Horst, D. A., Călin, G. A., & Li, Q. (2022) · Therapeutic Advances in Medical Oncology · doi:10.1177/17588359221111703 · Cited by 38
Evolution and Progress of mRNA Vaccines in the Treatment of Melanoma: Future Prospects
Bafaloukos, D. I., Gazouli, I., Koutserimpas, C., & Samonis, G. (2023) · Vaccines · doi:10.3390/vaccines11030636 · Cited by 44
“However, immune escape may still occur; as shown by clinical trial data, 50% and 64% of melanoma patients, even under the potent combination of ipilimumab and nivolumab, will experience disease progression at 1 and at 5 years after treatment initiation, respectively [23].”
BackgroundDeciphering the complexities of cancer cell immune evasion: Mechanisms and therapeutic implications
Gupta, I., Hussein, O., Sastry, K. S., Bougarn, S., Gopinath, N., Chin-Smith, E. C., Sinha, Y., Korashy, H. M., & Maccalli, C. (2023) · Advances in Cancer Biology - Metastasis · doi:10.1016/j.adcanc.2023.100107 · Cited by 39
Nguyen, C. B., Reimers, M. A., Perera, C. D., Abida, W. M., Chou, J., Feng, F. Y.-C., Antonarakis, E. S., McKay, R. R., Pachynski, R. K., Zhang, J., et al. (2024) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-24-0400 · Cited by 42
Su, X., Li, J., Xu, X., Ye, Y., Wang, C., Pang, G., Liu, W., Liu, A., Zhao, C., & Hao, X. (2024) · Journal of Translational Medicine · doi:10.1186/s12967-024-05552-6 · Cited by 45
“Furthermore, nivolumab plus ipili-mumab group demonstrated a longer median PFS compared to the nivolumab group and the ipilimumab group [11.5 months (95% CI 8.7–19.3) versus 6.9 months (95% CI 5.1–10.2) versus 2.9 months (95% CI 2.8–3.2)] in treating advanced melanoma [15].”
BackgroundInfluentialYang, C., Sánchez-Vega, F., Chang, J. C., Chatila, W. K., Shoushtari, A. N., Ladanyi, M., Travis, W. D., BUSAM, K. J., & Rekhtman, N. (2020) · Modern Pathology · doi:10.1038/s41379-020-0594-0 · Cited by 39
Herck, Y. V., Antoranz, A., Andhari, M. D., Milli, G., Bechter, O. E., Smet, F. D., & Bosisio, F. M. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.636681 · Cited by 40
First line treatment of BRAF mutated advanced melanoma: Does one size fit all?
Giugliano, F., Crimini, E., Tarantino, P., Zagami, P., Uliano, J., Corti, C., Trapani, D., Curigliano, G., & Ascierto, P. A. (2021) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2021.102253 · Cited by 37
Self-citation
Metadata
- Authors
- Larkin, J., Chiarion-Sileni, V., Gonzalez, R., Grob, J.-J., Rutkowski, P., Lao, C. D., Cowey, C. L., Schadendorf, D., Wagstaff, J., Dummer, R., Ferrucci, P. F., Smylie, M., Hogg, D., Hill, A., Márquez-Rodas, I., Haanen, J., Guidoboni, M., Maio, M., Schöffski, P., Carlino, M. S., Lebbé, C., McArthur, G., Ascierto, P. A., Daniels, G. A., Long, G. V., Bastholt, L., Rizzo, J. I., Balogh, A., Moshyk, A., Hodi, F. S., & Wolchok, J. D.
- Affiliations
- Royal Marsden NHS Foundation Trust (GB)
- From the Royal Marsden NHS Foundation Trust, London (J.L.), and the College of Medicine, Swansea University, Swansea (J.W.) — both in the United Kingdom; the Oncology Institute of Veneto IRCCS, Padua (V.C.-S.), the European Institute of Oncology, IRCCS, Milan (P.F.F.), Istituto Nazionale Tumori IRCCS Fondazione Pascale, Naples (P.A.A.), the Immunotherapy and Somatic Cell Therapy Unit, IRCCS Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori, Meldola (M.G.), and the Center for Immuno...
- University of Siena (IT)
- The University of Sydney (AU)
- ORCID
- Larkin, James
- Gonzalez, Rene
- Grob, Jean-Jacques
- Rutkowski, Piotr
- Schadendorf, Dirk
- Wagstaff, John
- Dummer, Reinhard
- Ferrucci, Pier F.
- Smylie, Michael
- Hogg, David
- Haanen, John
- Guidoboni, Massimo
- Maio, Michele
- Schöffski, Patrick
- Carlino, Matteo S.
- McArthur, Grant
- Ascierto, Paolo A.
- Daniels, Gregory A.
- Long, Georgina V.
- Bastholt, Lars
- Moshyk, Andriy
- Hodi, F. Stephen
- Wolchok, Jedd D.
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2019-10-17
- Volume
- 381
- Issue
- 16
- Pages
- 1535-1546
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W3043703771
- Cited by
- 3,723
- References
- 14
- Citations by year
- 2026: 257 · 2025: 366 · 2024: 560 · 2023: 656 · 2022: 693 · 2021: 712 · 2020: 453 · 2019: 18
- FWCI
- 195.72
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- Zurich Open Repository and Archive (University of Zurich) (acceptedVersion, other-oa)
- University of Southern Denmark Research Portal (University of Southern Denmark) (submittedVersion, other-oa)
- Universitätsbibliographie, Universität Duisburg-Essen (submittedVersion)
- Lirias (submittedVersion)
- Institutional Research Information System University of Ferrara (University of Ferrara) (submittedVersion, other-oa)
- Use Siena air (University of Siena) (submittedVersion)
- Zurich Open Repository and Archive (University of Zurich) (submittedVersion, other-oa)
- Zurich Open Repository and Archive (University of Zurich)
- Funders
- Amgen
- Bristol-Myers Squibb
- Eli Lilly and Company
- Pfizer
- AstraZeneca
- GlaxoSmithKline
- Sanofi
- Array BioPharma
- Regeneron Pharmaceuticals
- Massachusetts Medical Society
- Les Laboratories Pierre Fabre
- Incyte
- Syndax Pharmaceuticals
- National Institute for Health and Care Research
- Eisai
- Ipsen
- Plexxikon
- EUSA Pharma
- LEO Pharma
- Genentech
- EMD Serono
- Sanofi Genzyme
- Pharmacyclics
- National Cancer Institute (P30CA008748)
- Topics
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Health Sciences › Medicine › Oncology › Cutaneous Melanoma Detection and Management
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Melanoma and MAPK Pathways
- Keywords
- ipilimumab, advanced melanoma, combination immunotherapy, immune checkpoint inhibitors, five-year survival, overall survival, progression-free survival, long-term outcomes, health-related quality of life, CheckMate 067, PD-1 inhibitors, CTLA-4 inhibitors, immune-related adverse events
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
